Severance Emily G, Yolken Robert H
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Stanley Division of Developmental Neurovirology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Curr Top Behav Neurosci. 2020;44:67-84. doi: 10.1007/7854_2018_84.
The study of microorganisms such as bacteria, viruses, archaea, fungi, and protozoa in the context of psychiatric disorders may be surprising to some. This intersection of disciplines, however, has a rich history and is currently revitalized by newfound functions of the microbiome and the gut-brain axis in human diseases. Schizophrenia, in particular, fits this model as a disorder with gene and environmental roots that may be anchored in the immune system. In this context, the combination of a precisely timed pathogen exposure in a person with genetically encoded altered immunity may have especially destructive consequences for the central nervous system (CNS). Furthermore, significant components of immunity, such as the development of the immune response and the concept of immune tolerance, are largely dictated by the commensal residents of the microbiome. When this community of microbes is imbalanced, perhaps as the result of a pathogen invasion, stress, or immune gene deficiency, a pathological cycle of localized inflammation, endothelial barrier compromise, translocation of gut-derived products, and systemic inflammation may ensue. If these pathologies enable access of gut and microbial metabolites and immune molecules to the CNS across the blood-brain barrier (BBB), and studies of the gut-brain axis support this hypothesis, a worsening of cognitive deficits and psychiatric symptoms is predicted to occur in susceptible individuals with schizophrenia. In this chapter, we review the role of microbes in various stages of this model and how these organisms may contribute to documented phenotypes of schizophrenia. An increased understanding of the role of pathogens and the microbiome in psychiatric disorders will better guide the development of microbial and immune-based therapeutics for disease prevention and treatment.
在精神疾病背景下对细菌、病毒、古菌、真菌和原生动物等微生物的研究,可能会让一些人感到惊讶。然而,这一学科交叉领域有着丰富的历史,并且目前正因微生物组和肠道-脑轴在人类疾病中的新发现功能而焕发生机。精神分裂症尤其符合这种模式,它是一种具有基因和环境根源的疾病,可能与免疫系统有关。在这种情况下,在具有基因编码免疫改变的个体中,精确时机的病原体暴露可能会对中枢神经系统(CNS)产生特别具有破坏性的后果。此外,免疫的重要组成部分,如免疫反应的发展和免疫耐受的概念,在很大程度上由微生物组的共生菌决定。当这个微生物群落失衡时,可能是由于病原体入侵、压力或免疫基因缺陷,可能会引发局部炎症、内皮屏障受损、肠道衍生产物易位和全身炎症的病理循环。如果这些病理状况使得肠道和微生物代谢产物以及免疫分子能够穿过血脑屏障(BBB)进入中枢神经系统,并且对肠道-脑轴的研究支持这一假设,那么预计在患有精神分裂症的易感个体中,认知缺陷和精神症状会恶化。在本章中,我们回顾了微生物在该模型各个阶段的作用,以及这些生物体如何导致精神分裂症已记录的表型。对病原体和微生物组在精神疾病中作用的进一步了解,将更好地指导基于微生物和免疫的疾病预防和治疗疗法的开发。